Cyproheptadine Shortage: What Providers and Prescribers Need to Know in 2026

Cyproheptadine occupies a unique clinical niche: it's FDA-approved for allergic conditions but is frequently prescribed off-label for appetite stimulation, serotonin syndrome management, migraine prevention, and antidepressant-induced sexual dysfunction. While there is no formal national shortage of Cyproheptadine in 2026, patients do report difficulty finding it at certain pharmacies — and understanding why can help you guide them more effectively.

Current Supply Status: 2026

As of 2026, Cyproheptadine is not listed on the FDA Drug Shortage Database or the ASHP Drug Shortages List. Multiple generic manufacturers distribute the drug through major pharmaceutical wholesalers. The original brand, Periactin, was discontinued in the U.S. but all marketed generics are bioequivalent.

Localized stock-outs occur periodically, particularly for the oral solution (2 mg/5 mL). These typically resolve within 1-5 business days as pharmacies reorder from their wholesalers. The oral solution is stocked in smaller quantities at many retail pharmacies and may require a search across multiple locations.

Clinical Implications: When Patients Can't Find Cyproheptadine

For Allergic Indications

When patients cannot obtain Cyproheptadine for allergic rhinitis, urticaria, or conjunctivitis, second-generation H1 antihistamines are first-line alternatives with robust evidence and superior tolerability:

Cetirizine (Zyrtec): 10 mg QD; OTC; mildly sedating; appropriate for chronic urticaria and allergic rhinitis

Loratadine (Claritin): 10 mg QD; OTC; non-sedating; preferred for daytime use or elderly patients

Fexofenadine (Allegra): 180 mg QD or 60 mg BID; OTC; least sedating; must take on empty stomach

Hydroxyzine (Vistaril, Atarax): 10-25 mg QID PRN; Rx only; appropriate when sedation is not a concern or is desired; good option for urticaria and pruritus

For Pediatric Appetite Stimulation

Cyproheptadine is commonly prescribed off-label as an appetite stimulant in children with failure to thrive, cystic fibrosis, cancer cachexia, and anorexia nervosa (nonbulimic subtype). Typical dosing is 0.25 mg/kg/day divided BID-TID, usually as the oral solution (2 mg/5 mL).

If Cyproheptadine is temporarily unavailable for this indication, clinical options are limited. Mirtazapine (off-label, adolescents/adults) may be considered in appropriate patients. Nutritional supplementation and dietitian involvement should be optimized concurrently. In most cases where a localized stock-out is the issue, waiting 1-5 days for restock — rather than switching agents — is the most pragmatic approach.

For Serotonin Syndrome

Cyproheptadine (4-8 mg initial dose, up to 12 mg if needed, then 4 mg TID) is used as an adjunct in moderate-to-severe serotonin syndrome due to its 5-HT2A antagonism. An in vivo PET study demonstrated that cyproheptadine 4 mg TID blocked 85% of 5-HT2A receptors in the prefrontal cortex, and 6 mg TID blocked 95%.

When Cyproheptadine is unavailable for acute serotonin syndrome management, cornerstone management remains discontinuation of the causative agent, benzodiazepines for agitation and muscle rigidity, IV fluids, and temperature management. In severe refractory cases, chlorpromazine (with appropriate caution for hypotension) has been used as a serotonin antagonist.

Prescribing Considerations and Patient Counseling

Liquid vs. tablet availability: If prescribing for young children, note that the oral solution can be harder to source. Consider including both the tablet and solution on the prescription so pharmacies can fill whichever form is available, if clinically appropriate.

No controlled substance restrictions: Cyproheptadine is not DEA-scheduled, so early refills, large supply fills (90-day), and e-prescribing are all straightforward.

Compounding pharmacies: For patients who consistently struggle to find the oral solution, a local compounding pharmacy can prepare a custom suspension. This requires a prescription specifying the desired concentration and flavor.

Elderly patients: Cyproheptadine is on the AGS Beers Criteria as a potentially inappropriate medication for older adults due to anticholinergic effects. If an elderly patient cannot find Cyproheptadine, a second-generation antihistamine is generally preferable from a safety standpoint anyway.

How medfinder for Providers Can Help

When your patients report difficulty finding Cyproheptadine, medfinder for Providers can help your practice direct them to pharmacies with stock. The platform contacts pharmacies on behalf of the patient and delivers results by text — reducing the burden on your staff and ensuring patients get their medication faster.

Key Takeaways for Providers

No formal national shortage of Cyproheptadine exists in 2026 — localized stock-outs are typically short-lived

The oral solution (2 mg/5 mL) is harder to find than tablets — consider compounding as a contingency for pediatric patients

For allergic indications, second-generation antihistamines are clinically equivalent or superior with better tolerability

For pediatric appetite stimulation, the benefit of waiting for restock typically outweighs the risk of switching agents

Elderly patients on Cyproheptadine for allergies may benefit from transitioning to a second-generation antihistamine, which is already preferred per Beers Criteria

For a practical step-by-step guide to helping your patients locate Cyproheptadine, see: How to Help Your Patients Find Cyproheptadine In Stock: A Provider's Guide.